SuperworthAccendra Health free cash flow ACH
Cash from operations less capital spending, by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- −$337M
- Latest quarter, Q2 FY26
- −$73.6M
- Fiscal year 2025
- −$272.6M
Accendra Health's free cash flow was −$337M over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$73.6M.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | −$272.6M | n/a |
| FY2024 | −$49.4M | −109% |
| FY2023 | $549.8M | +229% |
| FY2022 | $166.9M | +101% |
| FY2021 | $83.2M | −71% |
| FY2020 | $288.8M | +134% |
| FY2019 | $123.7M | +75% |
| FY2018 | $70.7M | +219% |
| FY2017 | $22.2M | −87% |
| FY2016 | $167.4M | −33% |
| FY2015 | $249.1M | n/a |
| FY2014 | −$52.2M | −146% |
| FY2013 | $112.4M | −46% |
| FY2012 | $208.7M | +380% |
| FY2011 | $43.4M | −80% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$73.6M | n/a | −$337M | |
| Q1 FY26 | −$91.7M | n/a | −$283.4M | |
| Q4 FY25 | $55.1M | +574% | −$272.6M | |
| Q3 FY25 | −$226.8M | n/a | −$319.5M | |
| Q2 FY25 | −$20M | −128% | −$123M | |
| Q1 FY25 | −$80.9M | n/a | −$31.3M | |
| Q4 FY24 | $8.2M | −87% | −$49.4M | |
| Q3 FY24 | −$30.3M | −128% | $3.8M | |
| Q2 FY24 | $71.8M | −73% | $143.9M | |
| Q1 FY24 | −$99M | −188% | $338.6M | |
| Q4 FY23 | $61.4M | +61% | $549.8M | |
| Q3 FY23 | $109.7M | +411% | $526.6M |
Against its peers
Companies in Healthcare nearest Accendra Health's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| ACHAccendra Health | −2016.8% |
| NEPHNephros | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 10.3% |
| SPROSpero Therapeutics | n/m |
| LFVNLifevantage | 9.1% |
| ICCCImmucell | 4.5% |
| KEQUKewaunee Scientific | 11.5% |
| Peer median | 9.7% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Accendra Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.